Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera rises as it starts mid-stage trial for menopause drug

** Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading

** Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause

** Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co

** Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy

** Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL

** As of last close, stock up ~17% over the past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))

Recent news on AbCellera Biologics

See all news